All Stories

  1. Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters

    Article • Nature Microbiology, April 2023, Springer Science + Business Media

    Dr. Michael D. Muehlebach

  2. A protective measles virus-derived vaccine inducing long-lasting immune responses against influenza A virus H7N9

    Article • npj Vaccines, March 2023, Springer Science + Business Media

    Dr. Michael D. Muehlebach

  3. Protocol to dissociate healthy and infected murine- and hamster-derived lung tissue for single-cell transcriptome analysis

    Article • STAR Protocols, March 2023, Elsevier

    Dr. Michael D. Muehlebach

  4. Concentrating all helper protein functions on a single entity allows rescue of recombinant measles virus by transfection of just two plasmids

    Article • Journal of General Virology, November 2022, Society for General Microbiology

    Dr. Michael D. Muehlebach

  5. Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines

    Article • npj Vaccines, October 2022, Springer Science + Business Media

    Dr. Michael D. Muehlebach

  6. Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization

    Article • Cell Reports, August 2022, Elsevier

    Dr. Michael D. Muehlebach, Dr Richard Brown

  7. Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies

    Article • Viruses, July 2021, MDPI AG

    Dr. Michael D. Muehlebach

  8. The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection

    Article • Journal of General Virology, April 2021, Society for General Microbiology

    Dr. Michael D. Muehlebach

  9. A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine

    Article • Proceedings of the National Academy of Sciences, November 2020, Proceedings of the National Academy of Sciences

    Dr. Michael D. Muehlebach

  10. In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges

    Article • Science, October 2020, American Association for the Advancement of Science

    Dr. Michael D. Muehlebach

  11. Measles virus in cancer therapy

    Article • Current Opinion in Virology, April 2020, Elsevier

    Dr. Michael D. Muehlebach

  12. Development of Entry-Targeted Oncolytic Measles Viruses

    Article • September 2019, Springer Science + Business Media

    Dr. Michael D. Muehlebach

  13. Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma

    Article • Molecular Therapy — Oncolytics, March 2019, Elsevier

    Dr. Michael D. Muehlebach

  14. A Measles Virus-Based Vaccine Candidate Mediates Protection against Zika Virus in an Allogeneic Mouse Pregnancy Model

    Article • Journal of Virology, November 2018, ASM Journals

    Dr. Michael D. Muehlebach

  15. Modular MLV-VLPs co-displaying ovalbumin peptides and GM-CSF effectively induce expansion of CD11b + APC and antigen-specific T cell responses in vitro

    Article • Molecular Immunology, September 2018, Elsevier

    Dr. Michael D. Muehlebach

  16. Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model

    Article • Virology, August 2018, Elsevier

    Dr. Michael D. Muehlebach

  17. Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles

    Article • Scientific Reports, December 2017, Springer Science + Business Media

    Dr. Michael D. Muehlebach

  18. Vaccine platform recombinant measles virus

    Article • Virus Genes, July 2017, Springer Science + Business Media

    Dr. Michael D. Muehlebach

  19. Development of Recombinant Measles Virus-Based Vaccines

    Article • January 2017, Springer Science + Business Media

    Dr. Michael D. Muehlebach

  20. Production and purification of virus particles for the use in cancer therapy

    Article • New Biotechnology, July 2016, Elsevier

    Dr. Michael D. Muehlebach

  21. APOBEC4 Enhances the Replication of HIV-1

    Article • PLoS ONE, June 2016, PLOS

    Dr. Michael D. Muehlebach

  22. Suppressing active replication of a live attenuated simian immunodeficiency virus vaccine does not abrogate protection from challenge

    Article • Virology, February 2016, Elsevier

    Dr. Michael D. Muehlebach

  23. Abstract B040: Oncolytic measles virus for tumor vaccination

    Article • Cancer Immunology Research, January 2016, American Association for Cancer Research (AACR)

    Dr. Michael D. Muehlebach

  24. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform

    Article • Journal of Virology, September 2015, ASM Journals

    Dr. Michael D. Muehlebach

  25. Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response

    Article • Journal of Virology, June 2015, ASM Journals

    Dr. Michael D. Muehlebach

  26. Oncolytic measles viruses produced at different scales under serum‐free conditions

    Article • Engineering in Life Sciences, March 2015, Wiley

    Dr. Michael D. Muehlebach

  27. High Secretion of Interferons by Human Plasmacytoid Dendritic Cells upon Recognition of Middle East Respiratory Syndrome Coronavirus

    Article • Journal of Virology, January 2015, ASM Journals

    Dr. Michael D. Muehlebach

  28. A single amino acid substitution in the measles virus F2 protein reciprocally modulates membrane fusion activity in pathogenic and oncolytic strains

    Article • Virus Research, February 2014, Elsevier

    Dr. Michael D. Muehlebach

  29. Oncolytic Viruses

    Article • January 2014, Springer Science + Business Media

    Dr. Michael D. Muehlebach

  30. DARPin-targeting of Measles Virus: Unique Bispecificity, Effective Oncolysis, and Enhanced Safety

    Article • Molecular Therapy, April 2013, Elsevier

    Dr. Michael D. Muehlebach

  31. Intrahepatic Application of Suicide Gene-Armed Measles Virotherapeutics: A Safety Study in Transgenic Mice and Rhesus Macaques

    Article • Human Gene Therapy Clinical Development, March 2013, Mary Ann Liebert Inc

    Dr. Michael D. Muehlebach

  32. Entwicklung eines Produktionsprozesses zur Herstellung von Masernviren für die Krebstherapie

    Article • Chemie Ingenieur Technik, July 2012, Wiley

    Dr. Michael D. Muehlebach

  33. Adherens junction protein nectin-4 is the epithelial receptor for measles virus

    Article • Nature, November 2011, Nature

    Dr. Michael D. Muehlebach

  34. DARPins: An Efficient Targeting Domain for Lentiviral Vectors

    Article • Molecular Therapy, April 2011, Elsevier

    Dr. Michael D. Muehlebach

  35. Mutation of a diacidic motif in SIV-PBj Nef impairs T-cell activation and enteropathic disease

    Article • Retrovirology, January 2011, Springer Science + Business Media

    Dr. Michael D. Muehlebach

  36. Functional HIV-2- and SIVsmmPBj- derived lentiviral vectors generated by a novel polymerase chain reaction-based approach

    Article • The Journal of Gene Medicine, April 2010, Wiley

    Dr. Michael D. Muehlebach

  37. Lentiviral vectors with measles virus glycoproteins – dream team for gene transfer?

    Article • Trends in Biotechnology, May 2009, Elsevier

    Dr. Michael D. Muehlebach

  38. Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity

    Article • Gene Therapy, February 2009, Springer Science + Business Media

    Dr. Michael D. Muehlebach

  39. The Measles Virus Fusion Protein Transmembrane Region Modulates Availability of an Active Glycoprotein Complex and Fusion Efficiency

    Article • Journal of Virology, September 2008, ASM Journals

    Dr. Michael D. Muehlebach

  40. Targeted Cell Entry of Lentiviral Vectors

    Article • Molecular Therapy, August 2008, Elsevier

    Dr. Michael D. Muehlebach

  41. Impact of viral accessory proteins of SIVsmmPBj on early steps of infection of quiescent cells

    Article • Virology, August 2007, Elsevier

    Dr. Michael D. Muehlebach

  42. Stable Transduction of Primary Human Monocytes by Simian Lentiviral Vector PBj

    Article • Molecular Therapy, December 2005, Elsevier

    Dr. Michael D. Muehlebach

  43. Genetic engineering of onco/lentivirus hybrids results in formation of infectious but not of replication-competent viruses

    Article • Journal of General Virology, March 2004, Society for General Microbiology

    Dr. Michael D. Muehlebach

  44. Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes

    Article • Journal of Molecular Medicine, December 2003, Springer Science + Business Media

    Dr. Michael D. Muehlebach

  45. A Novel Lentivirus Vector Derived from Apathogenic Simian Immunodeficiency Virus

    Article • Virology, December 2001, Elsevier

    Dr. Michael D. Muehlebach